Page last updated: 2024-09-04

canertinib and topotecan

canertinib has been researched along with topotecan in 2 studies

Compound Research Comparison

Studies
(canertinib)
Trials
(canertinib)
Recent Studies (post-2010)
(canertinib)
Studies
(topotecan)
Trials
(topotecan)
Recent Studies (post-2010) (topotecan)
1249652,392626792

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)topotecan (IC50)
Cytochrome P450 3A4Homo sapiens (human)1.5211
DNA topoisomerase 1Homo sapiens (human)0.8525
DNA topoisomerase 2-alphaHomo sapiens (human)0.605
DNA topoisomerase 2-betaHomo sapiens (human)0.605
Hypoxia-inducible factor 1-alphaHomo sapiens (human)0.06
Multidrug and toxin extrusion protein 2Homo sapiens (human)8.6
Multidrug and toxin extrusion protein 1Homo sapiens (human)1.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.17

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bible, KC; Boerner, SA; Erlichman, C; Hallgren, CG; James, CD; Kaufmann, SH; Maliepaard, M; Ross, DD; Scheffer, GL; Spieker, R; Wang, XY1

Other Studies

2 other study(ies) available for canertinib and topotecan

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Cancer research, 2001, Jan-15, Volume: 61, Issue:2

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Cycle; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Humans; Irinotecan; Morpholines; Neoplasm Proteins; Neoplastic Stem Cells; Phosphorylation; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay

2001